Thus, the data presented here further support the development of additional local or systemic perioperative therapies, preferentially aimed at GAP-43, the neuron-glioma synapses or other molecular drivers of the malignant tumor cell networks (13–16). The gene discussed is GAP43; the disease is central nervous system cancer.